Kardigan Posts 64-Cent Quarterly Loss as Cash Burn Draws Focus
KARD sits 28% above its 52-week low of $12.23.
Summary
Kardigan reported a third-quarter loss of 64 cents a share, with the quarterly loss totaling $58.6 million. It was the company's first quarterly print since the Q2 net loss of $116.2 million that included a $43.5 million non-cash charge from milestone liability revaluation. The company ended Q2 with $660.7 million in cash and investments, so the size of this quarter's burn is the number that matters for how long the pipeline stays funded. The loss lands days after Kardigan finished enrolling 156 patients in the Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, an event that came with an amended 8-K on November 6. With the trial now fully enrolled, spending shifts from enrollment to running the study, and the market will judge whether the loss reflects that step-up. No revenue or cash balance figures accompanied the headline, so the full 10-Q will carry the detail that determines whether this is a routine development-stage loss or a faster burn than expected.
At the time of this announcement, KARD was trading at $15.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $12.23 to $27.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.